Refine Results
- Applications and Industries
- Content Type
- Analysis Platform
- Language
- Publication Date
1 - 8 of 8 results
Recently updated Cancer Immunotherapy Handbook featuring the latest high impact xCELLigence publications and newly released supporting information.
Describes use of a tethering approach to immobilize liquid tumor cell lines on to the surface of gold biosensors embedded in an Agilent E-Plate.
To determine if the stimulation of endogenously expressed GPCRs can be monitored by the xCELLigence system, cells were stimulated with various receptor agonists, triggering either Gs-, Gi-, or Gq-mediated downstream signals.
AACR 2025 poster: Chronic anti-CD3/CD28 stimulation during cell expansion generates exhausted T cells with a distinct metabolic and cytotoxic phenotype
This editorial showcases Agilent solutions for metabolic modulation enhancing CAR T-cell activation, persistence, and serial killing for improved cancer immunotherapy
This editorial will discuss the potency assays available for cellular immunotherapies, the regulatory criteria they must meet, and the challenges faced in measuring immune cell cytotoxicity.
Although cell therapies have shown great promise in clinical studies, challenges with the large scale manufacturing of these therapies still need to be addressed.
Dr. Daniel Hui from Tmunity Therapeutics addresses challenges with cell therapy development with an innovative CAR-T toolbox, using xCELLigence RTCA for measuring potency of immune cell therapies.